Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 13, 2022

Prognostic Value of TARC and Quantitative PET Parameters in Relapsed/Refractory Hodgkin Lymphoma Treated With Brentuximab Vedotin and DHAP



Additional Info

Disclosure statements are available on the authors' profiles:

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
Leukemia 2022 Oct 14;[EPub Ahead of Print], J Driessen, MJ Kersten, L Visser, A van den Berg, SH Tonino, JM Zijlstra, PJ Lugtenburg, F Morschhauser, M Hutchings, S Amorim, T Gastinne, M Nijland, GJC Zwezerijnen, R Boellaard, HCW de Vet, AIJ Arens, R Valkema, RDK Liu, EEE Drees, D de Jong, WJ Plattel, A Diepstra

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading